Related Experiment Video
Updated: Mar 23, 2026
11:41
Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
Published on: March 10, 2015
8.3K
Meeting Report: 2015 PDA Virus & TSE Safety Forum.
Hannelore Willkommen1, Johannes Blümel2, Kurt Brorson3
1Regulatory Affairs & Biological Safety Consulting, Erzhausen, Germany.
PDA Journal of Pharmaceutical Science and Technology
|March 30, 2016
Summary
The 2015 PDA Virus & TSE Safety Forum highlighted advancements in detecting emerging viruses and ensuring safety in pharmaceutical products. Discussions covered next-generation sequencing, prion inactivation, and regulatory updates for virus and transmissible spongiform encephalopathy (TSE) safety.
Area of Science:
- Biotechnology and Pharmaceutical Safety
- Virology and Prion Science
Background:
- The Parenteral Drug Association (PDA) Virus & TSE Safety Forum convenes experts to discuss critical safety aspects in drug development.
- The 2015 forum focused on emerging viruses, advanced detection methods, and Transmissible Spongiform Encephalopathy (TSE) safety, crucial for regulatory compliance.
Purpose of the Study:
- To summarize key discussions and findings from the 2015 PDA Virus & TSE Safety Forum.
- To provide insights into regulatory perspectives, technological advancements, and scientific understanding of virus and TSE safety in the pharmaceutical industry.
Main Methods:
- Compilation of presentations and discussions from the forum.
- Review of regulatory updates from European and US agencies.
- Analysis of data on virus detection, clearance, and prion inactivation.
Main Results:
- Emerging viruses and novel detection systems were discussed, alongside the safety of cell substrates and raw materials.
- Progress in next-generation sequencing (NGS) for viral safety assessment was showcased.
- Effectiveness of virus inactivation/removal methods and prion inactivation strategies were presented, including epidemiological reviews of variant Creutzfeldt-Jakob disease.
Conclusions:
- The forum facilitated essential information exchange between industry, research, and regulatory bodies on virus and TSE safety.
- Advancements in detection and inactivation technologies are crucial for ensuring the safety of pharmaceutical products.
- Continued dialogue and research are vital for addressing evolving challenges in viral and prion safety.
Related Concept Videos
01:25Arboviral Encephalitis
8
Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...
8
01:18Viral Meningitis
30
Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
30